Compare PRU & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRU | IQV |
|---|---|---|
| Founded | 1875 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Life Insurance | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 35.1B |
| IPO Year | 2001 | 2013 |
| Metric | PRU | IQV |
|---|---|---|
| Price | $124.78 | $236.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $103.71 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | ★ 33.20 | 4.67 |
| EPS | ★ 4.48 | 1.61 |
| Revenue | ★ $60,774,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | N/A | $6.77 |
| Revenue Next Year | $3.06 | $5.89 |
| P/E Ratio | ★ $27.85 | $150.02 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $91.89 | $154.50 |
| 52 Week High | $127.72 | $251.36 |
| Indicator | PRU | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 61.19 |
| Support Level | $99.91 | $220.71 |
| Resistance Level | $127.72 | $247.52 |
| Average True Range (ATR) | 2.64 | 8.04 |
| MACD | -0.20 | -0.45 |
| Stochastic Oscillator | 70.37 | 42.46 |
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2025 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 39% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 11% of its 2025 adjusted earnings. PGIM had around $1.47 trillion in assets under management at the end of fourth-quarter 2025.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.